Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFANELLI, C.
dc.contributor.authorFERNANDES, B. H. V.
dc.contributor.authorMACHADO, F. G.
dc.contributor.authorOKABE, C.
dc.contributor.authorMALHEIROS, D. M. A. C.
dc.contributor.authorFUJIHARA, C. K.
dc.contributor.authorZATZ, R.
dc.date.accessioned2017-11-27T16:23:31Z
dc.date.available2017-11-27T16:23:31Z
dc.date.issued2011
dc.description.abstractFanelli C, Fernandes BH, Machado FG, Okabe C, Malheiros DM, Fujihara CK, Zatz R. Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation. Am J Physiol Renal Physiol 301: F580-F587, 2011. First published June 8, 2011; doi:10.1152/ajprenal.00042.2011.-We recently standardized a model (L(Lact)) of severe chronic kidney disease based on impaired nephrogenesis by suppression of angiotensin II activity during lactation (Machado FG, Poppi EP, Fanelli C, Malheiros DM, Zatz R, Fujihara CK. Am J Physiol Renal Physiol 294: F1345-F1353, 2008). In this new study of the L(Lact) model, we sought to gain further insight into renal injury mechanisms associated with this model and to verify whether the renoprotection obtained with the association of the angiotensin II receptor blocker losartan (L) and hydrochlorothiazide (H), which arrested renal injury in the remnant kidney model, would provide similar renoprotection. Twenty Munich-Wistar dams, each nursing six pups, were divided into control, untreated, and L(Lact) groups, given losartan (L; 250 mg.kg(-1).day(-1)) until weaning. The male LLact offspring remained untreated until 7 mo of age, when renal functional and structural parameters were studied in 17 of them, used as pretreatment control (L(Lact)Pre), and followed no further. The remaining rats were then divided among groups L(Lact) + V, untreated; L(Lact) + L, given L (50 mg.kg(-1).day(-1)) now as a therapy; L(Lact) + H, given H (6 mg.kg(-1).day(-1)); and L(Lact) + LH, given L and H. All parameters were reassessed 3 mo later in these groups and in age-matched controls. At this time, L(Lact) rats exhibited hypertension, severe albuminuria, glomerular damage, marked interstitial expansion/inflammation, enhanced cell proliferation, myofibroblast infiltration, and creatinine retention. L monotherapy normalized albuminuria and prevented hypertension and the progression of renal injury, inflammation, and myofibroblast infiltration. In contrast to the remnant model, the LH combination promoted only slight additional renoprotection, perhaps because of a limited tendency to retain sodium in L(Lact) rats.
dc.description.indexMEDLINE
dc.description.sponsorshipState of Sao Paulo Foundation for Research Support (FAPESP) [05/56066-3]
dc.description.sponsorshipBrazilian Council of Scientific and Technologic Development (CNPq) [304039/2006-3, 308638/2010-7]
dc.identifier.citationAMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, v.301, n.3, p.F580-F587, 2011
dc.identifier.doi10.1152/ajprenal.00042.2011
dc.identifier.issn1931-857X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/22610
dc.language.isoeng
dc.publisherAMER PHYSIOLOGICAL SOC
dc.relation.ispartofAmerican Journal of Physiology-Renal Physiology
dc.rightsrestrictedAccess
dc.rights.holderCopyright AMER PHYSIOLOGICAL SOC
dc.subjectangiotensin II
dc.subjectAT(1) receptor
dc.subjectthiazides
dc.subjectchronic kidney disease
dc.subject.otherchronic kidney-disease
dc.subject.otherrenal-function
dc.subject.otherinterstitial fibrosis
dc.subject.otherchronic hypoxia
dc.subject.otherangiotensin-ii
dc.subject.otherblood-pressure
dc.subject.otherprogression
dc.subject.otherinjury
dc.subject.othermodel
dc.subject.otherendocytosis
dc.subject.wosPhysiology
dc.subject.wosUrology & Nephrology
dc.titleEffects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus10
hcfmusp.contributor.author-fmusphcCAMILLA FANELLI
hcfmusp.contributor.author-fmusphcBIANCA HELENA VENTURA FERNANDES
hcfmusp.contributor.author-fmusphcFLAVIA GOMES MACHADO
hcfmusp.contributor.author-fmusphcCRISTIENE OKABE
hcfmusp.contributor.author-fmusphcDENISE MARIA AVANCINI COSTA MALHEIROS
hcfmusp.contributor.author-fmusphcCLARICE KAZUE FUJIHARA
hcfmusp.contributor.author-fmusphcROBERTO ZATZ
hcfmusp.description.beginpageF580
hcfmusp.description.endpageF587
hcfmusp.description.issue3
hcfmusp.description.volume301
hcfmusp.origemWOS
hcfmusp.origem.pubmed21653629
hcfmusp.origem.scopus2-s2.0-80052404815
hcfmusp.origem.wosWOS:000294551400015
hcfmusp.publisher.cityBETHESDA
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceFujihara CK, 2007, AM J PHYSIOL-RENAL, V292, pF1810, DOI 10.1152/ajprenal.00521.2006
hcfmusp.relation.referenceHaas CS, 2004, CONNECT TISSUE RES, V45, P73, DOI 10.1080/03008200490442644
hcfmusp.relation.referencePohl M, 2010, J BIOL CHEM, V285, P41935, DOI 10.1074/jbc.M110.150284
hcfmusp.relation.referenceWALLENSTEIN S, 1980, CIRC RES, V47, P1
hcfmusp.relation.referenceOroszlan M, 2010, TRANSPL IMMUNOL, V23, P125, DOI 10.1016/j.trim.2010.05.003
hcfmusp.relation.referenceEddy AA, 2000, PEDIATR NEPHROL, V15, P290
hcfmusp.relation.referenceVogt L, 2008, J AM SOC NEPHROL, V19, P999, DOI 10.1681/ASN.2007060693
hcfmusp.relation.referenceGarcia-Estan J, 2006, CLIN SCI, V110, P227, DOI 10.1042/CS20050165
hcfmusp.relation.referenceKang DH, 2001, J AM SOC NEPHROL, V12, P1448
hcfmusp.relation.referenceAbbate M, 2006, J AM SOC NEPHROL, V17, P2974, DOI 10.1681/ASN.2006040377
hcfmusp.relation.referenceJEPSEN FL, 1979, VIRCHOWS ARCH A, V383, P265, DOI 10.1007/BF00430245
hcfmusp.relation.referenceKLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186
hcfmusp.relation.referenceFine LG, 2008, KIDNEY INT, V74, P867, DOI 10.1038/ki.2008.350
hcfmusp.relation.referenceTUFROMCREDDIE A, 1995, AM J PHYSIOL-RENAL, V269, pF110
hcfmusp.relation.referenceNangaku M, 2006, J AM SOC NEPHROL, V17, P17, DOI 10.1681/ASN.2005070757
hcfmusp.relation.referenceHeyman SN, 2008, AM J NEPHROL, V28, P998, DOI 10.1159/000146075
hcfmusp.relation.referenceGonzalez-Villalobos R, 2005, AM J PHYSIOL-RENAL, V288, pF420, DOI 10.1152/ajprenal.00243.2004
hcfmusp.relation.referenceGuron G, 1997, HYPERTENSION, V29, P91
hcfmusp.relation.referenceKliem V, 1996, KIDNEY INT, V49, P666, DOI 10.1038/ki.1996.95
hcfmusp.relation.referenceKriz W, 1998, NEPHROL DIAL TRANSPL, V13, P2781, DOI 10.1093/ndt/13.11.2781
hcfmusp.relation.referenceLasaitiene D, 2004, AM J PHYSIOL-RENAL, V286, pF1144, DOI 10.1152/ajprenal.00236.2003
hcfmusp.relation.referenceMachado FG, 2008, AM J PHYSIOL-RENAL, V294, pF1345, DOI 10.1152/ajprenal.00020.2008
hcfmusp.relation.referenceMancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2
hcfmusp.relation.referenceMiyazaki Y, 1998, J CLIN INVEST, V102, P1489, DOI 10.1172/JCI4401
hcfmusp.relation.referenceNoronha IL, 2002, NEPHROL DIAL TRANSPL, V17, P363, DOI 10.1093/ndt/17.3.363
hcfmusp.relation.referenceRodriguez-Iturbe B, 2010, NEPHRON CLIN PRACT, V116, pC81, DOI 10.1159/000314656
hcfmusp.relation.referenceTanaka T, 2010, CURR OPIN NEPHROL HY, V19, P43, DOI 10.1097/MNH.0b013e3283328eed
hcfmusp.relation.referenceWu L L, 1997, Kidney Int Suppl, V63, pS221
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationbe85bfb0-767c-413d-94d1-dc8d8fc1a6db
relation.isAuthorOfPublicationf7e1c7dd-34ed-4bc2-906f-3682eb0d3fa9
relation.isAuthorOfPublicationdeafa5fe-63d9-46d8-890d-c3fea758824b
relation.isAuthorOfPublicationc1acb46d-26a5-47b4-bde4-a6f88c061301
relation.isAuthorOfPublicationf4c18531-1ddb-4687-aa09-bd1c33cabf12
relation.isAuthorOfPublicationd0c4098b-c47b-4f59-bf51-75f42e6b0abc
relation.isAuthorOfPublication6ef4951d-81a7-4a54-8d25-ae0aeb11124b
relation.isAuthorOfPublication.latestForDiscoverybe85bfb0-767c-413d-94d1-dc8d8fc1a6db
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_FANELLI_Effects_of_losartan_in_monotherapy_or_in_association_2011.PDF
Tamanho:
1.26 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16